These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25791210)

  • 21. Hydrogen exchange mass spectrometry for studying protein structure and dynamics.
    Konermann L; Pan J; Liu YH
    Chem Soc Rev; 2011 Mar; 40(3):1224-34. PubMed ID: 21173980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The application of MALDI TOF MS in biopharmaceutical research.
    Kafka AP; Kleffmann T; Rades T; McDowell A
    Int J Pharm; 2011 Sep; 417(1-2):70-82. PubMed ID: 21147205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Time-of-flight secondary-ion mass spectrometry for the surface characterization of solid-state pharmaceuticals.
    Prestidge CA; Barnes TJ; Skinner W
    J Pharm Pharmacol; 2007 Feb; 59(2):251-9. PubMed ID: 17270078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterizing rapid, activity-linked conformational transitions in proteins via sub-second hydrogen deuterium exchange mass spectrometry.
    Resetca D; Wilson DJ
    FEBS J; 2013 Nov; 280(22):5616-25. PubMed ID: 23663649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection and characterization of altered conformations of protein pharmaceuticals using complementary mass spectrometry-based approaches.
    Bobst CE; Abzalimov RR; Houde D; Kloczewiak M; Mhatre R; Berkowitz SA; Kaltashov IA
    Anal Chem; 2008 Oct; 80(19):7473-81. PubMed ID: 18729476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New developments in protein structure-function analysis by MS and use of hydrogen-deuterium exchange microfluidics.
    Landreh M; Astorga-Wells J; Johansson J; Bergman T; Jörnvall H
    FEBS J; 2011 Oct; 278(20):3815-21. PubMed ID: 21668648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of sucrose and benzyl alcohol on GCSF conformational dynamics revealed by hydrogen deuterium exchange mass spectrometry.
    Zhang J; Banks DD; He F; Treuheit MJ; Becker GW
    J Pharm Sci; 2015 May; 104(5):1592-600. PubMed ID: 25693946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody structural integrity of site-specific antibody-drug conjugates investigated by hydrogen/deuterium exchange mass spectrometry.
    Pan LY; Salas-Solano O; Valliere-Douglass JF
    Anal Chem; 2015 Jun; 87(11):5669-76. PubMed ID: 25938577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HDX-MS guided drug discovery: small molecules and biopharmaceuticals.
    Marciano DP; Dharmarajan V; Griffin PR
    Curr Opin Struct Biol; 2014 Oct; 28():105-11. PubMed ID: 25179005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protein analysis by hydrogen exchange mass spectrometry.
    Hoofnagle AN; Resing KA; Ahn NG
    Annu Rev Biophys Biomol Struct; 2003; 32():1-25. PubMed ID: 12598366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hydrogen-deuterium exchange mass spectrometry as an emerging analytical tool for stabilization and formulation development of therapeutic monoclonal antibodies.
    Majumdar R; Middaugh CR; Weis DD; Volkin DB
    J Pharm Sci; 2015 Feb; 104(2):327-45. PubMed ID: 25354868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Editorial and Review: 28th ASMS Sanibel Conference on Mass Spectrometry-Characterization of Protein Therapeutics by Mass Spectrometry.
    Sperry JB; Chen G; Loo JA
    J Am Soc Mass Spectrom; 2017 May; 28(5):781-785. PubMed ID: 28374311
    [No Abstract]   [Full Text] [Related]  

  • 33. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-resolution MS for structural characterization of protein therapeutics: advances and future directions.
    Wei H; Tymiak AA; Chen G
    Bioanalysis; 2013 May; 5(10):1299-313. PubMed ID: 23721450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advancements, challenges, and practical considerations in the mass spectrometry-based analytics of protein biotherapeutics: A viewpoint from the biosimilar industry.
    Háda V; Bagdi A; Bihari Z; Timári SB; Fizil Á; Szántay C
    J Pharm Biomed Anal; 2018 Nov; 161():214-238. PubMed ID: 30205300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surface analysis for compositional, chemical and structural imaging in pharmaceutics with mass spectrometry: a ToF-SIMS perspective.
    Barnes TJ; Kempson IM; Prestidge CA
    Int J Pharm; 2011 Sep; 417(1-2):61-9. PubMed ID: 21277966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Probing the non-covalent structure of proteins by amide hydrogen exchange and mass spectrometry.
    Smith DL; Deng Y; Zhang Z
    J Mass Spectrom; 1997 Feb; 32(2):135-46. PubMed ID: 9102198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Probing backbone dynamics with hydrogen/deuterium exchange mass spectrometry.
    Singh H; Busenlehner LS
    Methods Mol Biol; 2014; 1084():81-99. PubMed ID: 24061917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Technical decision making with higher order structure data: higher order structure characterization during protein therapeutic candidate screening.
    Jiang Y; Li C; Li J; Gabrielson JP; Wen J
    J Pharm Sci; 2015 Apr; 104(4):1533-8. PubMed ID: 25716705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydrogen/deuterium exchange mass spectrometry with top-down electron capture dissociation for characterizing structural transitions of a 17 kDa protein.
    Pan J; Han J; Borchers CH; Konermann L
    J Am Chem Soc; 2009 Sep; 131(35):12801-8. PubMed ID: 19670873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.